Correspondingly, HLA-A02+B62+B44−-related ‘indicator’ co-occurrence of KRAS G12D and TP53 mutations was verified to be significantly relevant to poor outcomes in stage I–II PAAD patients in both TCGA and ICGC cohort. The gene discussed is TP53; the disease is pancreatic adenocarcinoma.